Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.14), $0.27 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $63.74 million versus the consensus estimate of $15.79 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.